MagForce AG: MagForce USA, Inc. Completed Enrollment and Treatment for Stage 1 and Prepares for Next Stage of its Pivotal, Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with NanoTherm Therapy
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
